View article

Chronic hepatitis C is associated with increased morbidity and mortality in persons undergoing haemodialysis. This single‐arm, open‐label clinical trial investigated the safety and efficacy of an escalating dosage regimen of pegylated interferon (PEG‐IFN) alpha‐2b in this patient population. Patients with chronic hepatitis C who were undergoing haemodialysis began treatment with PEG‐IFN alpha‐2b at a dose of 0.5 μg/kg/week, which was increased every 4 weeks to a maximum of 1 μg/kg/week. Treatment duration was 24 weeks for patients with genotype (G) 2 or 3 infection and 48 weeks for patients with G1 infection. The primary end point was sustained virological response (SVR). Of 46 patients screened, 34 (G1: 70.6%; G3: 29.4%) were treated and 23 (67.6%) completed treatment. Overall, 85.3% of patients experienced early virological response, 52.9% experienced end‐of‐treatment response, and 50 …